{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":40,"n_cols":5,"rows_kept":40,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[5,2,5,3],[6,2,6,3],[7,2,7,3],[8,2,8,3],[9,2,9,3],[10,2,10,3],[11,2,11,3],[14,2,14,3],[14,4,14,5],[15,2,15,3],[15,4,15,5],[16,2,16,3],[18,2,18,3],[19,2,19,3],[20,2,20,3],[21,2,21,3],[29,2,29,3],[30,2,30,3],[33,2,33,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNISA996492368103316"]
[null,null,"Autore",null,"DEL VECCHIO, Mario <1958-    >"]
[null,null,"Titolo",null,"Guidare le aziende sanitarie nella crisi : il ruolo dei direttori generali : l'esperienza della Regione Lazio / Mario Del Vecchio, Anna Romiti"]
[null,null,"Pubbl/distr/stampa",null,"Milano, : EGEA, 2021"]
[null,null,"ISBN",null,"978-88-238-4736-1"]
[null,null,"Descrizione fisica",null,"XIII, 122 p. ; 24 cm"]
[null,null,"Collana",null,"S&R"]
[null,null,"Disciplina",null,"362.10684"]
[null,null,"Soggetti",null,"Aziende sanitarie - Gestione - Casi [:] Lazio"]
[null,null,"Collocazione",null,"362.106 DEL 1"]
[null,null,"Lingua di pubblicazione",null,"Italiano"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","In copertina: FIASO, Federazione italiana aziende sanitarie e ospedaliere"]
[null,"2.","Record Nr.",null,"UNINA9910502664303321"]
[null,null,"Titolo",null,"Imaging of inflammation and infection in cardiovascular diseases / / edited by Federico Caobelli"]
[null,null,"Pubbl/distr/stampa",null,"Cham, Switzerland : , : Springer, , [2021]"]
[{"$nulls":4},"©2021"]
[null,null,"ISBN",null,"3-030-81131-X"]
[null,null,"Descrizione fisica",null,"1 online resource (274 pages)"]
[null,null,"Disciplina",null,"616.12075"]
[null,null,"Soggetti",null,"Heart - Imaging"]
[{"$nulls":4},"Heart - Infections"]
[{"$nulls":4},"Malalties cardiovasculars"]
[{"$nulls":4},"Malalties del cor"]
[{"$nulls":4},"Diagnòstic per la imatge"]
[{"$nulls":4},"Infeccions"]
[{"$nulls":4},"Inflamació"]
[{"$nulls":4},"Llibres electrònics"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Nota di bibliografia","Includes bibliographical references."]
[null,null,"Nota di contenuto",null,"Intro -- Preface -- Contents -- Part I: Challenges in Patient Preparation -- 1: Challenges in Patient Preparation -- 1.1  Introduction -- 1.2  Prolonged Intervals of Fasting -- 1.3  Dietary Modifications -- 1.4  Pharmacologic Approaches -- 1.5  Conclusion -- References -- Part II: Non-ischemic Diseases -- 2: Cardiac Sarcoidosis -- 2.1  Introduction -- 2.2  Screening for Cardiac Sarcoidosis -- 2.3  Diagnosis -- 2.4  Endomyocardial Biopsy: Imaging Guidance -- 2.5  CMR for Diagnosis/CMR Imaging Protocol -- 2.6  Late Gadolinium Enhancement (LGE) -- 2.7  Imaging Myocardial Inflammation and Quantitative Tissue Characterization with CMR T1 and T2 Mapping -- 2.8  Additional CMR Findings Suggestive of Cardiac Sarcoidosis -- 2.9  Differential Diagnosis -- 2.10  Treatment: Anti-Inflammatory Therapy -- 2.11  CMR for Arrhythmogenic Risk Stratification/ICD -- 2.12  Positron Emission Tomography -- 2.13  Positron Emission Tomography with Tracers Other than 18F-FDG -- 2.14  Prognosis -- 2.15  Follow-up and Monitoring of Anti-Inflammatory Response -- 2.16  Hybrid PET-CMR Imaging -- 2.17  Outlook -- 2.18  Conclusion "]
[{"$nulls":4},"-- References -- 3: Cardiac Amyloidosis -- 3.1  Introduction -- 3.1.1  Different Phenotypes of Cardiac Amyloidosis -- 3.1.1.1  AL Amyloidosis -- 3.1.1.2  ATTR Amyloidosis -- 3.1.2  Screening for Cardiac Amyloidosis -- 3.2  Diagnosis -- 3.2.1  Endomyocardial Biopsy -- 3.2.2  Cardiac Magnetic Resonance (CMR) Imaging -- 3.2.2.1  CMR Diagnosis and Imaging Protocol -- 3.2.2.2  Late Gadolinium Enhancement (LGE) -- 3.2.2.3  Quantitative Tissue Characterization with CMR Native T1, T2 and ECV Mapping -- 3.2.2.4  Differential Diagnosis of AL vs. ATTR Amyloid -- 3.2.3  Scintigraphy -- 3.2.3.1  Bone Avid Radiotracers -- Imaging Protocols and Interpretation -- Diagnostic Accuracy -- 3.2.3.2  Innervation Radiotracers -- 3.2.4  Positron Emission Tomography (PET)."]
[{"$nulls":4},"3.2.5  Hybrid Imaging: PET/MRI -- 3.2.6  Diagnostic Algorithm for Diagnosis and Sub-Typing of Cardiac Amyloidosis -- 3.3  Treatment -- 3.4  Prognosis -- 3.5  Conclusion -- References -- Part III: Ischemic Diseases -- 4: Molecular Imaging of Vulnerable Plaque -- 4.1  Introduction -- 4.2  Biology and Pathogenesis of Atherosclerosis -- 4.2.1  History -- 4.2.2  Mechanisms of Atherosclerosis -- 4.2.2.1  Initiation of Atherosclerosis -- Vascular Endothelium and Atherosclerosis -- Hemodynamics Forces in Atherosclerosis -- Low-Density Lipoprotein Cholesterol -- Surface Adhesion Molecules -- Foam Cells Formation -- Progression of Atherosclerosis -- Smooth Muscle Cells and Atherosclerosis -- Calcification -- Plaque Neoangiogenesis -- Innate Immunity Cells in Atherosclerosis -- Adaptive Immunity in Atherosclerosis -- 4.2.3  Complication of Atherosclerosis -- 4.2.3.1  Inducible Ischemia -- 4.2.3.2  Plaque Rupture -- 4.2.3.3  Plaque Erosion -- 4.3  Metabolism of Glucose in Atherosclerosis -- 4.3.1  Glucose and Immune Cells -- 4.3.2  Imaging Inflammation in Atherosclerosis Using Glucose Metabolism -- 4.4  Targeting Chemokine Receptor Expression in Vulnerable Plaque -- 4.4.1  Technological Advancements: PET/MRI and Chemokine Receptor -- 4.4.2  Radiopharmaceutical Agents Advancements: Theragnostic and Chemochine Receptor -- 4.5  Targeting Microcalcification in Atherosclerosis -- 4.5.1  Atherosclerotic Plaque Calcium Deposition -- 4.5.2  Cardiovascular Risk Quantification -- 4.5.3  High/Risk Coronary Plaque Evaluation -- 4.5.4  Atherosclerotic Plaque Composition/Activity Assessment -- 4.6  Targeting Neovascularization in Atherosclerosis -- 4.7  Targeting SSRT-2 Receptor Expression in Atherosclerosis with DOTA-Derivatives-PET -- 4.8  Summary -- References -- 5: Post-Infarction Inflammatory Alterations -- 5.1  General Introduction."]
[{"$nulls":4},"5.2  Biology of Ventricular Remodeling -- 5.2.1  Pathobiology of Ventricular Remodeling Post-MI -- 5.2.2  The Inflammatory Response -- 5.2.2.1  Resident Inflammatory Cells -- Mast Cells -- Macrophages -- 5.2.2.2  Infiltrating Inflammatory Cells -- Polymorphonuclear Leukocytes -- Monocytes and Macrophages -- Dendritic Cells -- T and B Lymphocytes -- 5.2.2.3  Cardiomyocytes and ECM -- 5.2.3  Animal Models to Study Post-AMI Inflammation -- 5.2.3.1  Small Animal Models -- Open Chest -- Coronary Artery Ligation -- Topical Application of FeCl3 -- Closed Chest -- Isoproterenol Injection -- 5.2.3.2  Large Animal Models -- Open Chest -- Coronary Artery Ligation -- Gradual Constriction -- Hydraulic Occluder -- Topical Application of FeCl3 -- Closed Chest -- Balloon Inflation -- Embolization -- Endothelial Electrical Injury -- 5.3  The Role of Molecular Imaging -- 5.3.1  Cardiac MRI -- 5.3.2  Single-Photon Emission Computed Tomography -- 5.3.3  Positron Emission Tomography -- 5.4  Imaging Targets -- 5.4.1  Metabolic Activity -- 5.4.2  Labeled Cells -- 5.4.3  Membrane Receptors -- 5.4.4  "]
[{"$nulls":4},"Somatostatin Receptors -- 5.4.5  Mannose Receptor -- 5.4.6  Folate Receptor -- 5.4.7  Translocator Protein -- 5.4.8  Glucagon-like Peptide-1 Receptor (GLP-1R) -- 5.4.9  Chemokine Receptors -- 5.4.10  Lymphocyte Markers -- 5.4.10.1  Adhesion Molecules -- 5.4.10.2  Extracellular (Matrix) Components -- 5.5  Hybrid Imaging: The Added Value of Hybrid Imaging -- 5.6  Concluding Remarks -- References -- Part IV: Infection -- 6: Infection: Pericarditis -- 6.1  Pericardial Anatomy -- 6.2  Pericardial Pathologies -- 6.3  Aetiology and Pathophysiology -- 6.4  Clinical Manifestations and Diagnosis -- 6.5  Computed Tomography -- 6.6  Cardiovascular Magnetic Resonance (CMR) -- 6.6.1  Typical CMR Protocol for the Evaluation of Pericardial Disease -- 6.6.2  CMR and Acute Pericarditis."]
[{"$nulls":4},"6.6.3  CMR and Pericardial Effusions -- 6.6.4  CMR and Pericardial Constriction -- 6.6.5  Constrictive-Effusive Pericarditis -- 6.7  Molecular Imaging -- 6.8  Basics of Treatment -- 6.9  Conclusion -- References -- 7: Infection: Myocarditis -- 7.1  Introduction -- 7.2  Aetiology and Pathogenesis -- 7.3  From Acute Myocarditis to Chronic Inflammatory Cardiomyopathy and Heart Failure -- 7.4  Clinical Presentations and Diagnosis -- 7.5  Endomyocardial Biopsy -- 7.6  Cardiovascular Magnetic Resonance (CMR) -- 7.7  Infectious Inflammatory Cardiomyopathy -- 7.7.1  Idiopathic/Post-Viral Myocarditis -- 7.8  Coronavirus Disease-2019 (COVID-19) and Myocarditis -- 7.9  Non-Infectious Inflammatory Cardiomyopathy -- 7.9.1  Connective Tissue Disease -- 7.9.1.1  Systemic Lupus Erythematosus -- 7.9.1.2  Rheumatoid Arthritis -- 7.9.1.3  Systemic Sclerosis/Systemic Scleroderma -- 7.9.1.4  Behçet's Disease -- 7.9.1.5  Polyarteritis Nodosa -- 7.10  Eosinophilic Myocarditis/Endomyocardial fibrosis -- 7.10.1  EGPA -- 7.10.2  Infectious Endomyocarditis and Endomyocardial Fibrosis -- 7.10.3  Haematological -- 7.11  Drug-Induced or Toxic Myocarditis -- 7.12  Inflammatory Myositis -- 7.13  Giant Cell Myocarditis -- 7.14  Genetic Causes -- 7.15  Molecular Imaging -- 7.16  Hybrid Imaging -- 7.17  Summary -- References -- 8: Cardiac Devices Infection -- 8.1  Introduction -- 8.2  Scintigraphy in Cardiac Devices Infection -- 8.2.1  Radiolabelling of White Blood Cells with 99mTc-HMPAO or 111In-oxine -- 8.2.2  Image Acquisition -- 8.2.3  Image Interpretation -- 8.2.4  Radiolabelled WBC Scintigraphy of CIED Infection -- 8.2.5  Radiolabelled WBC Imaging of Left Ventricular Assist Devices Infection -- 8.2.6  Merits and Limitations of Radiolabelled WBC Scintigraphy in Cardiac Devices Infection: Alternative SPECT Tracers -- 8.3  FDG PET/CT Imaging of Cardiac Devices Infection."]
[{"$nulls":4},"8.3.1  Patient Preparation -- 8.3.1.1  Suppression of Myocardial FDG Uptake -- 8.3.1.2  Withdrawal of Medications -- 8.3.2  Image Acquisition and Interpretation -- 8.3.3  FDG PET/CT Imaging of CIED Infection -- 8.3.4  FDG PET/CT Imaging of LVAD Infection -- 8.3.5  FDG PET/CT for Extra-Cardiac Disease in Patients Assessed for Cardiac Devices Infection -- 8.4  Comparative Performance of Radionuclide WBC Scintigraphy and FDG PET/CT in Cardiac Devices Infection -- 8.5  Conclusion -- References -- 9: Endocarditis -- 9.1  Introduction -- 9.2  Single Photon Emission Tomography (SPECT) -- 9.2.1  67Ga-citrate Scintigraphy -- 9.2.2  Labelled Leukocytes Scintigraphy -- 9.2.3  Other SPECT Tracers -- 9.3  Positron Emission Tomography (PET) -- 9.4  Concluding Remarks -- References."]